CDKN2A and astrocytoma (excluding glioblastoma): Compared to histopathologic grade alone, the combination of CDKN2A/B loss, focal amplifications, and histopathologic grade better defined a group of IDH1/2-mutant astrocytoma patients with intermediate overall survival (Figure 2D).